Martin E. Cearnal - 17 Mar 2021 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Sr VP/Chief Commercial Officer, Director
Signature
Martin E. Cearnal by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
17 Mar 2021
Net transactions value
+$27,022
Form type
4
Filing time
08 Jun 2021, 17:22:46 UTC
Next filing
09 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Tax liability $9,483 -2,945 -1.9% $3.22 148,814 17 Mar 2021 Direct F1
transaction CPIX Common Stock Purchase $318 +105 +0.07% $3.03 148,919 16 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $319 +105 +0.07% $3.04 149,024 19 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $317 +105 +0.07% $3.02 149,129 20 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $312 +105 +0.07% $2.97 149,234 21 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $311 +105 +0.07% $2.96 149,339 22 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $314 +105 +0.07% $2.99 149,444 23 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $312 +105 +0.07% $2.97 149,549 26 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $309 +105 +0.07% $2.94 149,654 27 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $235 +80 +0.05% $2.94 149,734 28 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $303 +105 +0.07% $2.89 149,839 29 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $292 +105 +0.07% $2.78 149,944 30 Apr 2021 Direct F2
transaction CPIX Common Stock Purchase $279 +105 +0.07% $2.66 150,049 03 May 2021 Direct F2
transaction CPIX Common Stock Purchase $279 +105 +0.07% $2.66 150,154 04 May 2021 Direct F2
transaction CPIX Common Stock Purchase $287 +105 +0.07% $2.73 150,259 05 May 2021 Direct F2
transaction CPIX Common Stock Purchase $288 +105 +0.07% $2.74 150,364 06 May 2021 Direct F2
transaction CPIX Common Stock Purchase $287 +105 +0.07% $2.73 150,469 07 May 2021 Direct F2
transaction CPIX Common Stock Purchase $285 +105 +0.07% $2.71 150,574 10 May 2021 Direct F2
transaction CPIX Common Stock Purchase $281 +105 +0.07% $2.68 150,679 11 May 2021 Direct F2
transaction CPIX Common Stock Purchase $300 +105 +0.07% $2.86 150,784 12 May 2021 Direct F2
transaction CPIX Common Stock Purchase $302 +105 +0.07% $2.88 150,889 13 May 2021 Direct F2
transaction CPIX Common Stock Purchase $295 +105 +0.07% $2.81 150,994 14 May 2021 Direct F2
transaction CPIX Common Stock Purchase $13,850 +5,000 +3.3% $2.77 155,994 14 May 2021 Direct F3
transaction CPIX Common Stock Purchase $298 +105 +0.07% $2.84 156,099 17 May 2021 Direct F2
transaction CPIX Common Stock Purchase $16,131 +5,700 +3.7% $2.83 161,799 17 May 2021 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPIX Options (right to buy) Award $0 +5,000 $0.000000 5,000 17 Mar 2021 Common Stock 5,000 $3.22 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares.
F2 The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.715 to $2.792, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.805 to $2.8797, inclusive.
F5 100% vesting on March 17, 2025.